Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MESO)

Mesoblast to Host Analyst Call on Financial Results for Period Ended March 31, 2020

GlobeNewswire May 26, 2020

Clinical Outcomes Using RYONCIL(TM) (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles in Biology of Blood and Marrow Transplantation

GlobeNewswire May 25, 2020

Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS

GlobeNewswire May 13, 2020

First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome

GlobeNewswire May 6, 2020

Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment

GlobeNewswire April 30, 2020

83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblast's Cell Therapy Remestemcel-L

GlobeNewswire April 24, 2020

Mesoblast to Present Positive Clinical Outcomes Using Remestemcel-L in Patients With Inflammatory Lung Disease at 2020 International Society of Cell and Gene Therapy Annual Meeting

GlobeNewswire April 17, 2020

MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH'S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19

GlobeNewswire April 8, 2020

FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19

GlobeNewswire April 6, 2020

FDA ACCEPTS MESOBLAST'S BIOLOGICS LICENCE APPLICATION FOR RYONCIL(TM) AND AGREES TO PRIORITY REVIEW

GlobeNewswire April 1, 2020

CLINICAL OUTCOMES OF MESOBLAST'S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS

GlobeNewswire March 30, 2020

Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease

GlobeNewswire March 10, 2020

Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019

GlobeNewswire February 26, 2020

Mesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019

GlobeNewswire February 25, 2020

Consistent Outcomes Using Ryoncil(TM) as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD

GlobeNewswire February 24, 2020

Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease

GlobeNewswire February 20, 2020

Mesoblast Submits Completed Biologics License Application for Ryoncil(TM) to US FDA

GlobeNewswire February 3, 2020

Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco

GlobeNewswire January 15, 2020

Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L

GlobeNewswire January 2, 2020

Data Monitoring Committee Completes Final Scheduled Review of Mesoblast's Phase 3 Trial of Revascor in Advanced Chronic Heart Failure

GlobeNewswire December 18, 2019